Key Points
- Director Roelof Botha sold 75,000 shares at an average price of $236.12 for a total of $17,709,000, trimming his stake by 6.10% to 1,154,198 shares; the sale was disclosed via an SEC Form 4 filing.
- Natera missed EPS estimates, reporting ($0.64) vs. consensus ($0.39) while revenue rose 34.7% to $592.18 million; the company remains unprofitable (negative net margin ~14.6%) with a market cap around $32.7 billion and a 52-week range of $125.38–$241.28.
- Analyst sentiment is mixed-leaning positive with a MarketBeat consensus of "Moderate Buy" and an average target of about $220.88, including recent upgrades/target increases from Evercore (to $250) and Morgan Stanley (to $220); ratings breakdown: 15 Buys, 3 Holds, 2 Sells.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) Director Roelof Botha sold 75,000 shares of the business's stock in a transaction on Monday, November 24th. The shares were sold at an average price of $236.12, for a total transaction of $17,709,000.00. Following the completion of the sale, the director directly owned 1,154,198 shares in the company, valued at $272,529,231.76. This trade represents a 6.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Natera Stock Performance
NASDAQ:NTRA opened at $237.12 on Thursday. The company has a 50-day moving average of $190.07 and a 200-day moving average of $169.57. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $241.28. The company has a market capitalization of $32.72 billion, a price-to-earnings ratio of -103.55 and a beta of 1.75.
Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.25). The business had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business's revenue was up 34.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.26) EPS. Sell-side analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.
Institutional Trading of Natera
Large investors have recently made changes to their positions in the business. Siemens Fonds Invest GmbH raised its holdings in shares of Natera by 3.1% in the third quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company's stock valued at $290,000 after buying an additional 54 shares during the last quarter. Guided Capital Wealth Management LLC grew its holdings in Natera by 0.5% during the 2nd quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company's stock worth $2,219,000 after acquiring an additional 66 shares during the last quarter. BOKF NA increased its position in Natera by 1.9% in the 3rd quarter. BOKF NA now owns 3,733 shares of the medical research company's stock valued at $601,000 after acquiring an additional 69 shares in the last quarter. Silvant Capital Management LLC raised its stake in shares of Natera by 0.5% in the third quarter. Silvant Capital Management LLC now owns 13,488 shares of the medical research company's stock worth $2,171,000 after acquiring an additional 70 shares during the last quarter. Finally, Main Management ETF Advisors LLC lifted its position in shares of Natera by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company's stock worth $743,000 after purchasing an additional 72 shares in the last quarter. Institutional investors own 99.90% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms recently commented on NTRA. Evercore ISI raised their target price on Natera from $190.00 to $250.00 and gave the stock an "outperform" rating in a research report on Friday, November 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Natera in a report on Wednesday, October 8th. BNP Paribas Exane upgraded shares of Natera from an "underperform" rating to a "neutral" rating and set a $172.00 target price on the stock in a research note on Monday, October 27th. Wells Fargo & Company upped their target price on shares of Natera from $175.00 to $190.00 and gave the stock an "equal weight" rating in a report on Friday, November 7th. Finally, Morgan Stanley lifted their price target on shares of Natera from $195.00 to $220.00 and gave the company an "overweight" rating in a report on Tuesday, November 11th. Fifteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $220.88.
Read Our Latest Analysis on NTRA
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
